Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Resected well-differentiated thyroid neoplasms with at least one high risk feature will
receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control
rate at 2 years will be recorded.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
toxicity according to RTOG criteria
Harold Lau, MD
Tom Baker Cancer Centre
Canada: Health Canada